Endoscopic Injection of Ethanolamine as a Treatment for Achalasia: A First Report

Moretó, M; E, Ojembarrena; Rodriguez, M.

doi:10.1055/s-2007-1005551

Cited by 19 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reducing pressure of diffuse esophageal spasm (DES) by ethanolamine, used in scleroterapy of esophageal varices, has not found wider application, and the results have been followed up in short-term at the level of dilatation 28 . Research for alternative endoscopic modalities for achalasia treatment is under way all the time.…”

Section: Discussionmentioning

confidence: 99%

Long-term outcome of a modified balloon dilatation in the treatment of patients with achalasia

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term outcome of a modified balloon dilatation in the treatment of patients with achalasia

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Further research needs to be conducted to determine if these therapeutic modalities hold any promise. 32,33 Overall, botulinum toxin is part of the gastroenterologist's armamentarium to treat achalasia. Given the data, it may be a reasonable initial therapeutic option in patients diagnosed with achalasia as it does not appear to preclude more invasive treatments at a later time.…”

Section: Endoscopic Therapymentioning

confidence: 99%

Review article: the management of achalasia – a comparison of different treatment modalities¹

Lake¹,

Wong²

2006

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARY BackgroundAchalasia is an uncommon primary oesophageal motor disorder with an unknown aetiology. Therapeutic options for achalasia are aimed at decreasing the lower oesophageal sphincter pressure, improving the oesophageal empting, and most importantly, relieving the symptoms of achalasia. Modalities for treatment include pharmacologic, endoscopic, pneumatic dilatation and surgical. The decision of which modality to use involves the consideration of multiple clinical and economic factors.

show abstract

“…Two and four weeks later, the EO injection was repeated. The number of injections was extracted from the previous studies that have shown that two to seven sessions of injection are needed for alleviating the symptoms . Some of the patients needed more than three sessions of injection because of relapse.…”

Section: Methodsmentioning

confidence: 99%

Ethanolamine oleate as a novel therapy is effective in resistant idiopathic achalasia

et al. 2013

View full text Add to dashboard Cite

Idiopathic achalasia (IA) is a primary motor disorder of the esophagus. Recently, ethanolamine oleate (EO) has been introduced as a novel therapy in IA. We investigate the long-term efficacy of EO injection in the selected IA patients. Two hundred twenty patients with IA were evaluated prospectively. Thirty-one patients who were resistant to or poor candidate of pneumatic balloon dilation and/or cardiomyotomy were enrolled in this study. EO was injected into the lower esophageal sphincter three times at 2-week intervals. Patients were evaluated with the achalasia symptom score (ASS), timed barium esophagogram, and manometry before and after the injections. A good response was defined as a greater than 50% reduction from baseline in the ASS, height and/or volume of barium in TBE, and absence of severe dysphagia or regurgitation at 1.5 months after the last injection. Relapse was defined as two or more points increase in dysphagia score after an initial good response. The mean age of patients was 49.32 ± 19.3 years. Twenty-nine patients had a good response and two had a poor response. The mean ASS decreased from 12.48 (±2.06) to 4.50 (±2.96) (P = 0.0001), and the mean volume of barium decreased from 115.35 (±93.40) to 45.50 (±60.86) mL at 1.5 months after the last injection (P = 0.0001).The mean lower esophageal sphincter pressure was 30.47 ± 13.95 before the treatment and decreased to 14.30 ± 11.89 at 1.5 months after the treatment. (P = 0.0001). The mean duration of follow up was 30.16 ± 11.3 (18-68) months. Twelve patients in whom symptoms relapsed were treated effectively with reinjection. In some patients, minor complications (chest pain and erosion in the distal esophagus) occurred. This study indicates that EO has a long-term effect and can be considered for use in the selected IA patients.

show abstract

Endoscopic Injection of Ethanolamine as a Treatment for Achalasia: A First Report

Cited by 19 publications

References 0 publications

Long-term outcome of a modified balloon dilatation in the treatment of patients with achalasia

Long-term outcome of a modified balloon dilatation in the treatment of patients with achalasia

Review article: the management of achalasia – a comparison of different treatment modalities¹

Ethanolamine oleate as a novel therapy is effective in resistant idiopathic achalasia

Contact Info

Product

Resources

About

Endoscopic Injection of Ethanolamine as a Treatment for Achalasia: A First Report

Cited by 19 publications

References 0 publications

Long-term outcome of a modified balloon dilatation in the treatment of patients with achalasia

Long-term outcome of a modified balloon dilatation in the treatment of patients with achalasia

Review article: the management of achalasia – a comparison of different treatment modalities1

Ethanolamine oleate as a novel therapy is effective in resistant idiopathic achalasia

Contact Info

Product

Resources

About

Review article: the management of achalasia – a comparison of different treatment modalities¹